IGF-2 LR3Check methods and identity
What a 2026 Placenta Study Measured About IGF2 and Birth Weight
1 numbered sourceSource years 2026
Peptides are short chains of amino acids joined by peptide bonds. Larger chains, such as insulin-like growth factor II, can transmit growth signals. Native IGF-II is studied in fetal development because signals in the placenta and fetal circulation can be related to growth. The label IGF-2 LR3 has not been matched to a defined material here. A study of native IGF2 in human tissue helps explain the biology of a related name, without establishing effects of that label. [1]
Felix Chelslín and colleagues analyzed samples from infants born at term in three birth-weight categories. They measured gene expression in placental samples and compared selected protein measurements in placenta and blood. Placental IGF2 gene expression was lower in the group born small for gestational age. Cord blood concentrations of IGF-II tended to increase across the groups from smaller to larger birth weight. Maternal blood measures did not show the same differences. [1]
The study demonstrates why the source of a sample matters. A reading from cord blood is not the same as a reading from maternal blood or a measure of how much messenger RNA a placenta contains. The groups were defined by observed birth weights. They were not randomly assigned to have higher or lower growth-factor concentrations. The associations do not settle whether a measured difference caused the difference in size, followed from it or shared another cause. [1]
These were measurements of naturally occurring biology, without treatment with an IGF analog. They cannot establish that adding a growth factor improves birth outcomes. They also cannot identify a product called IGF-2 LR3. Their value is in showing where native IGF2-related measurements differed, and which comparisons a follow-up study would need to address. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
